Keyphrases
Somatostatin
100%
Disease Severity
100%
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
100%
Disease Progression
100%
Egfr
62%
Lanreotide
50%
Cyclic Adenosine Monophosphate (cAMP)
37%
Non-associated
25%
Vasopressin V2 Receptor Antagonist
25%
Tolvaptan
25%
I-125
12%
24-hour Urine Collection
12%
Protein Intake
12%
Kidney Function
12%
Iothalamate Clearance
12%
Radioimmunoassay
12%
Concentration Change
12%
Ravine
12%
Therapy Efficacy
12%
Cyst Formation
12%
MRI Volumetry
12%
Total Kidney Volume
12%
Medicine and Dentistry
Disease Exacerbation
100%
Polycystic Kidney Disease
100%
Disease Severity
100%
Somatostatin
100%
Angiopeptin
50%
Cyclic AMP
37%
Receptor Antagonist
25%
Tolvaptan
25%
Vasopressin V2 Receptor
25%
Biological Marker
12%
Magnetic Resonance Imaging
12%
Urinary System
12%
Kidney Function
12%
Immunoassay
12%
Protein Intake
12%
Observational Study
12%
Enzyme Linked Immunosorbent Assay
12%
Iodine 125
12%
Iotalamic Acid
12%
Volumetry
12%
Agricultural and Biological Sciences
Somatostatin
100%
Lanreotide
100%
Cyclic AMP
75%
Receptor
50%
Eicosanoid Receptor
50%
Annuals
50%
Vasopressin
50%
Tolvaptan
50%
Magnetic Resonance Imaging
25%
Protein Intake
25%
Urinary System
25%
Immunoassay
25%
Renal Function
25%
Observational Studies
25%
Gully
25%
Pharmacology, Toxicology and Pharmaceutical Science
Disease Exacerbation
100%
Kidney Polycystic Disease
100%
Disease Severity
100%
Somatostatin
100%
Angiopeptin
50%
Cyclic AMP
37%
Receptor Antagonist
25%
Tolvaptan
25%
Vasopressin V2 Receptor
25%
Biological Marker
12%
Observational Study
12%
Enzyme-Linked Immunosorbent Assay
12%
Iodine-125
12%
Iotalamic Acid
12%
Immunoassay
12%
Neuroscience
Somatostatin
100%
Autosomal Dominant Polycystic Kidney
100%
Lanreotide
50%
Cyclic Adenosine Monophosphate
37%
Receptor Antagonist
25%
Tolvaptan
25%
Vasopressin V2 Receptor
25%
Magnetic Resonance Imaging
12%
Iodine-125
12%
ELISA
12%
Immunoassay
12%
Biochemistry, Genetics and Molecular Biology
Autosomal Dominant Polycystic Kidney
100%
Somatostatin Blood Level
100%
Lanreotide
50%
Cyclic Adenosine Monophosphate
37%
Receptor Antagonist
25%
Vasopressin
25%
Tolvaptan
25%
Kidney Function
12%
Observational Study
12%
Iodine-125
12%
Immunoassay
12%